ALC vs IONS
Alcon Inc vs Ionis Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
| Metric | ALC | IONS |
| AI Score |
68
|
43
|
| Price |
$75.39
|
$55.38
|
| P/E Ratio |
45.39×
|
-16.02×
|
| ROE |
4.4%
|
-77.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
98.2%
|
| Debt / Equity |
0.24×
|
5.50×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
46.6
|
| Beta |
0.703
|
0.4
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus IONS.
ALC leads by 25 points.
ALC scores 68/100 (Buy) versus IONS at 43/100 (Reduce).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
IONS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value